2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Bioinformatics, Treatment Considerations, Therapy Sequence, Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Human
PAPER

1234 A common GRK5 variant enhances PAR1-dependent platelet procoagulant activity and thrombin generation

Nina Shaver, Hannah Thomson2, Xuefei Zhao, MS3, Li Zhu, MD, PhD4, Francis Ayombil, PhD5, Amrita Sarkar, PhD6, Rodney Camire, PhD7, Mortimer Poncz, MD8, Peisong Ma, PhD9
1 Thomas Jefferson University, Philadelphia, United States
2 Thomas Jefferson University, Philadelphia, United States
3 Thomas Jefferson University, Philadelphia, United States
4 Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China
5 Children's Hospital of Philadelphia, Philadelphia, United States
6 Children's Hospital of Philadelphia, Philadelphia, United States
7 Children's Hospital of Philadelphia, Philadelphia, United States, The University of Pennsylvania Perelman School of Medicine Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, United States
9 Thomas Jefferson University, Philadelphia, United States

Background: Thrombin is a central mediator of hemostasis and thrombosis that activates platelets through the G protein-coupled receptors (GPCRs) PAR1 and PAR4 in humans. We previously demonstrated that G protein-coupled receptor kinase 5 (GRK5) negatively regulates platelet activation and thrombus formation by limiting PAR1-dependent signaling. We recently identified a common intronic GRK5 variant (rs10886430, A→G), homozygous in ~5 million Americans, that reduces GRK5 expression in platelets and enhances PAR1-mediated platelet activation. The variant is associated with an increased risk of venous thromboembolic diseases, including pulmonary embolism (PE) and deep vein thrombosis (DVT). Emerging evidence indicates that platelets are critical initiators and amplifiers of venous thrombus formation by providing procoagulant phosphatidylserine (PS)-rich surfaces that support localized thrombin generation.  However, whether the GRK5 GG genotype enhances platelet procoagulant activity and thrombin generation remains unknown.

Aim: We hypothesized that the GRK5 rs10886430 GG genotype enhances PAR1-dependent platelet procoagulant activity and thrombin generation, thereby contributing to venous thrombosis.

Methods: Whole blood and washed platelets from human donors with AA and GG genotypes were used to perform thrombin generation assays and to assess procoagulant activity by flow cytometry and using a HUVEC-based microfluidic flow chamber. In vivo thrombosis was evaluated using inferior vena cava (IVC) stasis and PE models in WT and platelet-specific Grk5-/- mice.  

Results: Flow cytometric analysis demonstrated that GG donors displayed an increased percentage of Annexin V+/P-selectin+ procoagulant platelets compared with AA donor platelets following stimulation with the PAR1 agonist peptide TRAP6, but not the PAR4 agonist peptide AYP, indicating that the GG genotype selectively enhances PAR1-dependent platelet procoagulant activity. GG donor platelets exhibited increased platelet adhesion and accumulation, PS exposure (Annexin V binding), and fibrin deposition on the hematoporphyrin-injured HUVECs compared with AA donor platelets. Thrombin generation assays demonstrated that GG donor platelets generated higher peak thrombin levels than AA donor platelets following stimulation with either tissue factor (extrinsic pathway) or Actin-FS (intrinsic pathway). To determine whether loss of GRK5 promotes venous thrombosis in vivo, we evaluated PE incidence after IVC stasis assays in platelet-specific Grk5-/- mice. Histological examination of perfused lungs revealed a higher incidence of PE in Grk5-/- mice (83%) compared with WT mice (14%), supporting a role for platelet GRK5 deficiency in promoting venous thrombosis and PE.

Conclusions: Together, these findings demonstrate that the GRK5 rs10886430 GG genotype enhances PAR1-dependent platelet procoagulant activity and thrombin generation, providing a mechanistic explanation for the increased risk of venous thromboembolism associated with this common variant. These findings further suggest that the GRK5 rs10886430 GG genotype may serve as a biomarker for identifying individuals at increased risk of venous thromboembolism and may help guide precision antithrombotic therapy.

Nina Shaver: No relevant conflicts of interest to declare.